Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Danshen Dropping Pill (CDDP) is a traditional Chinese patent medicine formulation primarily composed of extracts from *Salvia miltiorrhiza* (Danshen), *Panax notoginseng* (Sanqi), and Borneol. It is widely used in China for the treatment of cardiovascular diseases, particularly coronary heart disease (CHD) and angina pectoris. The formulation exerts its therapeutic effects through multiple pathways, including antiplatelet aggregation, anti-inflammatory actions, and protection of the vascular endothelium. Clinical research, including studies conducted at West China Hospital, has evaluated its impact on heart and artery structure and function in patients with comorbid CHD and hypertension. It is manufactured as a dropping pill, which allows for both oral and sublingual administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Danshen Dropping Pill.